Why this case matters

Usher syndrome type 2A is most often recognized as a condition affecting hearing and vision. It is caused by disease-causing changes in both copies of the USH2A gene and classically involves congenital or early-onset sensorineural hearing loss followed by retinitis pigmentosa, a progressive retinal disorder. Epilepsy is not considered a typical feature of USH2A-related Usher syndrome.

A 2026 case report in Molecular Syndromology describes an 11-year-old boy with epilepsy, cognitive decline, and a sleep-related electroencephalogram (EEG) pattern called developmental and epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS). Exome sequencing unexpectedly identified a diagnosis of USH2A-related Usher syndrome type 2A. The report is important because it shows how genetic testing can uncover an actionable diagnosis even when a child’s initial symptoms point toward a different medical problem.

The clinical picture: seizures, sleep EEG changes, and learning decline

The child first developed focal seizures occurring at night. Early EEG recordings showed epileptiform discharges—abnormal bursts of electrical activity—arising from the left occipital region of the brain. Over time, he experienced cognitive and academic decline, and his EEG evolved into a pattern consistent with EE-SWAS.

In EE-SWAS, abnormal spike-wave activity becomes especially prominent during sleep. This pattern is associated with developmental or cognitive difficulties in affected children and can be challenging to treat. In this case, the epilepsy course was treatment-resistant. Magnetic resonance imaging, including a repeat scan using 3-Tesla imaging, did not reveal a structural brain abnormality that could explain the seizures or EEG findings.

The combination of parental consanguinity, a difficult-to-control epilepsy course, and no explanatory finding on brain imaging led clinicians to pursue exome sequencing. This test examines the protein-coding portions of many genes at once, making it useful when symptoms do not clearly fit one known condition.

An unexpected USH2A diagnosis

Exome sequencing found a homozygous pathogenic USH2A variant: c.802G>A; p.(Gly268Arg). “Homozygous” means the child had the same disease-causing variant in both copies of the gene. Each parent carried one copy of the variant, consistent with recessive inheritance.

This result prompted targeted evaluations for features of Usher syndrome. Hearing testing confirmed bilateral moderate-to-moderately severe sensorineural hearing loss, with pure-tone averages of 60 dB HL in the right ear and 50 dB HL in the left ear. Retinal involvement was not clinically apparent at the time of assessment.

That finding fits the known natural history of Usher syndrome type 2A: hearing loss may be present early, while retinal disease can become evident later. The absence of recognizable retinal findings at one point in time does not remove the value of ongoing ophthalmologic surveillance in a person with confirmed biallelic USH2A disease.

One condition—or two?

A central question raised by this report is whether the USH2A variant also explains the epilepsy and EE-SWAS. The authors conclude that this is most plausibly a coincidental dual diagnosis, rather than an expanded form of USH2A-related disease.

This interpretation is based on current evidence: epilepsy is not an established feature of USH2A-related Usher syndrome, and this specific variant has not previously been associated with epilepsy or EE-SWAS in published literature. A single case cannot establish that a gene causes a new neurological feature. Instead, the report highlights an important reality of genetic medicine: one person can have more than one condition, and not every symptom must be attributed to a single genetic finding.

For families, this distinction matters. It avoids incorrectly redefining Usher syndrome type 2A as an epilepsy syndrome while still ensuring that the confirmed USH2A diagnosis receives appropriate attention.

Implications for care and future treatment planning

The genetic result did not establish a new epilepsy treatment target in this case. However, it changed care in a meaningful way by directing attention to hearing and eye health. A confirmed USH2A diagnosis supports planned audiologic follow-up and ophthalmologic monitoring for retinal changes, even if vision is currently unaffected.

More broadly, the case illustrates the role of broad genetic testing in children with unexplained or treatment-resistant neurological conditions. Exome sequencing may identify a diagnosis that is not obvious from the presenting symptoms but still affects long-term management, family counseling, surveillance, and future eligibility for disease-specific research opportunities.

The report also reinforces the need for careful interpretation of genetic results. Clinicians and researchers must distinguish between a finding that explains the presenting neurological disorder and one that identifies an additional, clinically important condition.

Looking ahead

As exome and genome testing become more integrated into clinical care, dual diagnoses may be recognized more often. Each well-documented case can help researchers refine the known boundaries of inherited diseases, while avoiding premature conclusions about new gene–symptom links.

For the Usher syndrome community, this report emphasizes a hopeful and practical message: genetic testing can reveal important information before all expected features are visible. Earlier recognition of USH2A-related disease can support proactive hearing and retinal care, strengthen understanding of inheritance within families, and connect individuals to the evolving landscape of Usher syndrome research.